Work

An Essential Parameters of Fosinopril Include Objectives, Indications, Mechanism of Action, Administration, Adverse Effects, Contra - Indications, Toxicity and Health Care Team Out Comes

Year: 2026

Type: article

Abstract: Angiotensin-converting enzyme (ACE) inhibitors, which have been used to treat cardiovascular diseases for almost thirty years, are related to fosinopril. Both heart failure and hypertension can now be treated with fosinopril, according to the US Food and Drug Administration (FDA). As a competitive inhibitor of ACE, fosinopril prevents angiotensin I from becoming an effective vasoconstrictor, angiotensin II. The following additional ACE inhibitors are authorized in the US: trandolapril, captopril, enalapril, lisinopril, benazepril, quinapril, ramipril, moexipril, and fosinopril. HIV-associated nephropathy, diabetic nephropathy, and acute myocardial infarction are the conditions for which fosinopril is used off-label. The drug's hydrophilicity, resistance to hepatic breakdown, and extended half-life set it apart from enalapril and captopril. This exercise highlights the role of the interprofessional healthcare team in managing hypertension with fosinopril by providing information on the drug's mechanism of action, pharmacology, adverse event profiles, eligible patient categories, and monitoring.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.19810548

Authors: Srinivas G., Ramanjaneyulu D.V., Satyanarayana Murthy S., Muralinath E., Guruprasad M., Hari Kiran M., Shaik Mahabooob Basha, Kundara Giridhar Reddy, Kasireddy Guthami, Mopoori Kalyan, Sai Charan B., Sainath Reddy T., Ramesh U., Rahul P., Rajitha V.

Language: English

Topic: Renin-Angiotensin System Studies

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7156334405

FWCI:

Cites:

Cited by:

Related to: